- New generation of oncological diagnostics;
- Cell mutations identification at the earliest stages, long before clinical manifestations;
- Identification of two new universal markers DNaseX / Apo10 and TKTL1 in activated monocytes (macrophages);
- Early detection of cancer recurrence;
- Simplicity of the study (only a blood sample is required).
EDIM-test is the innovatory test of a new generation of oncological diagnostics that reveals the accumulation of cellular mutations, leading to the malignant tumors development, at the earliest stage. Clinical studies published in the International Journal of Molecular Sciences in April 2017 have proven the ability of EDIM technology to detect tumors via “liquid biopsy” and to assess their malignancy statistically 21 months before their determination using classical oncomarkers.
EDIM (Epitope Detection In Monocytes) is based on the combined determination of two new universal markers DNaseX / Apo10 and TKTL1 in activated monocytes (macrophages). Macrophages are the immune system cells that actively penetrate body tissues and absorb pathogens, as well as tumor cells. Upon return to the blood flow, macrophages contain absorbed fragments of structures, so-called epitopes, that activate the immune defense against these foreign and undesirable components in the body. To detect the absorbed tumor structures, macrophages are examined for the presence of two tumor markers DNaseX / Apo10 and TKTL1.
The detection of DNaseX / Apo10 indicates an apoptosis impairment (programmed cell death), i.e. “degenerate” cells, avoiding the natural regulation of growth and growing uncontrollably. Elevated values of TKTL1 point to the cells with fermentation metabolism, which is associated with the increased aggressiveness, metastatic process and resistance to therapy. In particular, prostate cancer, breast cancer, squamous cell carcinoma, etc., can be detected using this technology with a sensitivity of 95.8% and a specificity of 97.3%. In addition, the EDIM blood test can also be used to detect early cancer relapse.
Early diagnosis of cancer using EDIM test is extremely simple (only a blood sample is required), does not bear risks and therefore can be conducted regularly at short intervals.